Skip to main content
SpringerLink
Log in

Recent Developments in Treatment Stratification for Metastatic Breast Cancer

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The modern approach to management of metastatic breast cancer (MBC) is centred on individualizing treatment to best suit the patient’s breast cancer characteristics (molecular subtype, disease burden and prognostic markers), as well as the patient’s clinical history (co-morbidities, prior therapies and social factors). The wealth of treatments available has heightened the complexity of tailored patient care that in turn allows better optimization of treatment efficacy and quality of life. There are promising developments in the management of estrogen receptor (ER)-positive breast cancer, particularly with respect to overcoming resistance with dual targeting of the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin and ER-signalling pathways. A central focus in the management of triple negative breast cancer has been through efforts to identify novel therapeutic targets in this disease subgroup. Next-generation sequencing approaches have begun to reveal how breast cancer somatic mutational heterogeneity between tumours with the same histopathological subtype is likely to impede efforts to identify novel common therapeutic targets.

The most successful example of targeted therapy in MBC is the targeting of human epidermal growth factor receptor 2 (HER2) by trastuzumab. Dual and irreversible HER2/epidermal growth factor receptor targeting and attenuation of downstream resistance pathways also appear promising in HER2-positive trastuzumab-refractory breast cancer. Targeted therapy with antiangiogenic agents shows clinical activity, but the balance between efficacy, toxicity and cost remains a topic of debate, emphasizing the unmet need for a predictive biomarker of response to this class of drug. Poly(ADP ribose) polymerase (PARP) inhibitors appear to have clinically meaningful activity in BRCA germline mutant breast cancer. Activity of PARP inhibitors in other breast cancer subgroups is yet to be clearly defined. Novel chemotherapy agents show marginally superior efficacy, at a cost of a moderate increase in toxicity. Bone-modifying drugs expand supportive care options; again, better permitting individualization of treatment choice. The future management of MBC will increasingly focus on stratifying therapeutics based on individualized-tumour molecular aberrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 102(7): 456–63

    Article  PubMed  Google Scholar 

  2. Ross MB, Buzdar AU, Smith TL, et al. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 1985; 55(2): 341–6

    Article  PubMed  CAS  Google Scholar 

  3. Patel JK, Nemoto T, Vezeridis M, et al. Does more intense palliative treatment improve overall survival in metastatic breast cancer patients? Cancer 1986; 57(3): 567–70

    Article  PubMed  CAS  Google Scholar 

  4. Brincker H. Distant recurrence in breast cancer: survival expectations and first choice of chemotherapy regimen. Acta Oncol 1988; 27(6A): 729–32

    Article  PubMed  CAS  Google Scholar 

  5. Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 2010; 341: c3620

    Article  PubMed  Google Scholar 

  6. Cold S, Jensen NV, Brincker H, et al. The influence of chemotherapy on survival after recurrence in breast cancer: a population-based study of patients treated in the 1950s, 1960s and 1970s. Eur J Cancer 1993; 29A(8): 1146–52

    Article  PubMed  CAS  Google Scholar 

  7. Chia SK, Speers CH, D’Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110(5): 973–9

    Article  PubMed  Google Scholar 

  8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783–92

    Article  PubMed  CAS  Google Scholar 

  9. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23(24): 5542–51

    Article  PubMed  CAS  Google Scholar 

  10. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17(8): 2355–64

    PubMed  CAS  Google Scholar 

  11. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747–52

    Article  PubMed  CAS  Google Scholar 

  12. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22(9): 1605–13

    Article  PubMed  CAS  Google Scholar 

  13. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009; 27(27): 4530–5

    Article  PubMed  CAS  Google Scholar 

  14. Robertson JF, Lindemann JPO, Llombart-Cussac A, et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the ‘FIRST’ Study. San Antonio Breast Cancer Symposium; 2010 Dec 8–12; San Antonio (TX)

  15. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28(30): 4594–600

    Article  PubMed  CAS  Google Scholar 

  16. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26(10): 1664–70

    Article  PubMed  CAS  Google Scholar 

  17. Bartsch R, Mlineritsch B, Gnant M, et al. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Res Treat 2009; 115(2): 373–80

    Article  PubMed  Google Scholar 

  18. Mlineritsch B, Psenak O, Mayer P, et al. Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. Breast Cancer Res Treat 2007; 106(1): 105–12

    Article  PubMed  CAS  Google Scholar 

  19. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21(11): 2101–9

    Article  PubMed  CAS  Google Scholar 

  20. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26(30): 4883–90

    Article  PubMed  CAS  Google Scholar 

  21. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18(22): 3758–67

    CAS  Google Scholar 

  22. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18(22): 3748–57

    PubMed  CAS  Google Scholar 

  23. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009; (4): CD003370

  24. Moyo VM, Higgins MJ, Aravelo-Araujo R, et al. A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), HER2-negative breast cancer [abstract]. ASCO Meeting Abstracts 2011; 29 (15 Suppl.): TPS112

    Google Scholar 

  25. Yue W, Fan P, Wang J, et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007; 106(1–5): 102–10

    Article  PubMed  CAS  Google Scholar 

  26. deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10(23): 8059–67

    Article  Google Scholar 

  27. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27(27): 4536–41

    Article  PubMed  CAS  Google Scholar 

  28. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008; 44(1): 84–91

    Article  PubMed  CAS  Google Scholar 

  29. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27(16): 2630–7

    Article  PubMed  CAS  Google Scholar 

  30. Chow LWC, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium; 2006 Dec 14–17; San Antonio (TX)

  31. Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). San Antonio Breast Cancer Symposium; 2010 Dec 8–12; San Antonio (TX)

  32. Ebbinghaus S, Blum JL, Cortes J, et al. A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer [abstract]. ASCO Meeting Abstracts 2011; 29 (15 Suppl.): TPS110

    Google Scholar 

  33. Andre F, Bachelot TD, Campone M, et al. A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer [abstract]. ASCO Meeting Abstracts 2011; 29 (15 Suppl.): 508

    Google Scholar 

  34. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27(18): 2954–61

    Article  PubMed  CAS  Google Scholar 

  35. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010; 28(25): 3922–8

    Article  PubMed  CAS  Google Scholar 

  36. Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377(9769): 914–23

    Article  PubMed  CAS  Google Scholar 

  37. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25(23): 3421–7

    Article  PubMed  CAS  Google Scholar 

  38. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23(12): 2726–34

    Article  PubMed  CAS  Google Scholar 

  39. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25(23): 3399–406

    Article  PubMed  CAS  Google Scholar 

  40. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25(33): 5210–7

    Article  PubMed  CAS  Google Scholar 

  41. Hortobagyi GN, Gomez HL, Li RK, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010; 122(2): 409–18

    Article  PubMed  CAS  Google Scholar 

  42. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010; 28(20): 3256–63

    Article  PubMed  CAS  Google Scholar 

  43. Vahdat LT, Vrdoljak E, Gomez H, et al. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer [abstract]. ASCO Meeting Abstracts 2011; 29 (15 Suppl.): 1083

    Google Scholar 

  44. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005; 93(3): 293–301

    Article  PubMed  CAS  Google Scholar 

  45. Ghersi D, Wilcken N, Simes J, et al. Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2005; (2): CD003366

  46. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26(12): 1980–6

    Article  PubMed  CAS  Google Scholar 

  47. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37(13): 1590–8

    Article  PubMed  CAS  Google Scholar 

  48. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8(7): 1263–8

    PubMed  CAS  Google Scholar 

  49. Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 7(1): 63–7

    Article  PubMed  CAS  Google Scholar 

  50. John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003; 284(1): L187–96

    PubMed  CAS  Google Scholar 

  51. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23(31): 7794–803

    Article  PubMed  CAS  Google Scholar 

  52. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27(22): 3611–9

    Article  PubMed  CAS  Google Scholar 

  53. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358(16): 1663–71

    Article  PubMed  CAS  Google Scholar 

  54. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112(7): 1455–61

    Article  PubMed  CAS  Google Scholar 

  55. Harries M, Ellis P, Harper P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J Clin Oncol 2005; 23(31): 7768–71

    Article  PubMed  CAS  Google Scholar 

  56. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008; 26(12): 1987–92

    Article  PubMed  CAS  Google Scholar 

  57. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009; 9(1): 29–33

    Article  PubMed  Google Scholar 

  58. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13(8): 2329–34

    Article  PubMed  CAS  Google Scholar 

  59. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13 (15 Pt 1): 4429–34

    Article  PubMed  Google Scholar 

  60. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363(20): 1938–48

    Article  PubMed  CAS  Google Scholar 

  61. Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 2004; 4(10): 814–9

    Article  PubMed  CAS  Google Scholar 

  62. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25(43): 5846–53

    Article  PubMed  CAS  Google Scholar 

  63. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26(14): 2126–32

    Article  PubMed  CAS  Google Scholar 

  64. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005; 5(4): 388–93

    Article  PubMed  CAS  Google Scholar 

  65. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28(7): 1145–53

    Article  PubMed  CAS  Google Scholar 

  66. Staudacher L, Cottu PH, Dieras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011; 22(4): 848–56

    Article  PubMed  CAS  Google Scholar 

  67. Uhm JE, Park YH, Yi SY, et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 2009; 124(6): 1457–62

    Article  PubMed  CAS  Google Scholar 

  68. Villarreal-Garza CM, Clemons M, Kassam F, et al. Platinum-based chemotherapy in triple-negative breast cancer [abstract]. ASCO Meeting Abstracts 2011; 29 (15 Suppl.): 1090

    Google Scholar 

  69. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010; 121(2): 261–71

    Article  PubMed  CAS  Google Scholar 

  70. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666–76

    Article  PubMed  CAS  Google Scholar 

  71. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28(20): 3239–47

    Article  PubMed  CAS  Google Scholar 

  72. Brufsky A, Rivera RR, Hurvitz SA, et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC) [abstract]. ASCO Meeting Abstracts 2010; 28 (15 Suppl.): 1021

    Google Scholar 

  73. Baselga J, Stemmer S, Pego A, et al. Cetuximab+cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. San Antonio Breast Cancer Symposium; 2010 Dec 8–12; San Antonio (TX)

  74. Mullooly M, McGowan PM, Sukor SU, et al. ADAMs as new therapeutic targets for triple-negative breast cancer [abstract]. ASCO Meeting Abstracts 2011; 29 (15 Suppl.): 1062

    Google Scholar 

  75. Ponzo MG, Lesurf R, Petkiewicz S, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 2009; 106(31): 12903–8

    Article  PubMed  CAS  Google Scholar 

  76. Genentech. A study evaluating the safety and efficacy of MedMAb in combination with paclitaxel and bevacizumab in patients with metastatic, triple-negative breast cancer [ClinicalTrials.gov identifier NCT01186991]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 4]

  77. Cancer Research UK. Abiraterone acetate in treating post-menopausal women with advanced or metastatic breast cancer [ClinicalTrials.gov identifier NCT00755885]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 4]

  78. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669–76

    Article  PubMed  CAS  Google Scholar 

  79. Albrecht I, Kopfstein L, Strittmatter K, et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One 2010; 5(11): e14109

    Article  PubMed  CAS  Google Scholar 

  80. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29(10): 1252–60

    Article  PubMed  CAS  Google Scholar 

  81. Brufsky A, Bondarenko IN, Smirnov V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. San Antonio Breast Cancer Symposium; 2009 Dec 9–13; San Antonio (TX)

  82. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29(6): 632–8

    Article  PubMed  CAS  Google Scholar 

  83. US Food and Drug Administration. Avastin (bevacizumab): process for removal of breast cancer indication begun, 2010 [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237280.htm [Accessed 2010 Dec 16]

  84. Bear HD, Tang G, Rastogi P, et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40 [abstract]. ASCO Meeting Abstracts 2011; 29 (15 Suppl.): LBA1005

    Google Scholar 

  85. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). San Antonio Breast Cancer Symposium; 2010 Dec 8–12; San Antonio (TX)

  86. National Surgical Adjuvant Breast and Bowel Project (NSABP). BETH study: treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab [ClinicalTrials.gov identifier NCT00625898]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 4]

  87. Swanton C, Larkin JM, Gerlinger M, et al. Predictive bio-marker discovery through the parallel integration of clinical trial and functional genomics datasets [letter]. Genome Med 2010; 2(8): 53

    Article  PubMed  CAS  Google Scholar 

  88. PREDICT Consortium. Personalised RNA interference to enhance the delivery of individualised cytotoxic and targeted therapeutics, 2011 [online]. Available from URL: http://www.predictconsortium.eu/ [Accessed 2011 Jul 15]

  89. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26(22): 3785–90

    Article  PubMed  CAS  Google Scholar 

  90. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917–21

    Article  PubMed  CAS  Google Scholar 

  91. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66(16): 8109–15

    Article  PubMed  CAS  Google Scholar 

  92. Dobzhansky T. Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 1946; 31(3): 269–90

    Google Scholar 

  93. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451(7182): 1111–5

    Article  PubMed  CAS  Google Scholar 

  94. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361(2): 123–34

    Article  PubMed  CAS  Google Scholar 

  95. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376(9737): 235–44

    Article  PubMed  CAS  Google Scholar 

  96. Sandhu SK, Wenham RM, Wilding G, et al. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers [abstract]. ASCO Meeting Abstracts 2010; 28 (15 Suppl.): 3001

    Google Scholar 

  97. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11(14): 5175–80

    Article  PubMed  CAS  Google Scholar 

  98. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26(15): 2568–81

    Article  PubMed  Google Scholar 

  99. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92(7): 564–9

    Article  PubMed  CAS  Google Scholar 

  100. O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364(3): 205–14

    Article  PubMed  Google Scholar 

  101. O’Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) [abstract]. ASCO Meeting Abstracts 2011; 29 (15 Suppl.): 1007

    Google Scholar 

  102. Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract]. ASCO Meeting Abstracts 2010; 28 (15 Suppl.): 3002

    Google Scholar 

  103. Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [abstract]. ASCO Meeting Abstracts 2010; 28 (15 Suppl.): 1019

    Google Scholar 

  104. Swanton C, Burrell RA, Futreal PA. Breast cancer genome heterogeneity: a challenge to personalised medicine? Breast Cancer Res 2011; 13(1): 104

    Article  PubMed  Google Scholar 

  105. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23(19): 4265–74

    Article  PubMed  CAS  Google Scholar 

  106. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005; 353(16): 1673–84

    Article  PubMed  CAS  Google Scholar 

  107. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659–72

    Article  PubMed  CAS  Google Scholar 

  108. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. ASCO Meeting Abstracts 2007; 25 (18 Suppl.): 512

    Google Scholar 

  109. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354(8): 809–20

    Article  PubMed  CAS  Google Scholar 

  110. Pegram MD, O’Callaghan C. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations. Clin Breast Cancer 2001; 2 Suppl. 1: S15–9

    Article  PubMed  Google Scholar 

  111. Pegram MD, Konecny GE, O’Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96(10): 739–49

    Article  PubMed  CAS  Google Scholar 

  112. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29(2): 149–56

    Article  PubMed  CAS  Google Scholar 

  113. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29(3): 264–71

    Article  PubMed  CAS  Google Scholar 

  114. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study. J Clin Oncol 2009; 27(12): 1999–2006

    Article  CAS  Google Scholar 

  115. Burris 3rd HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29(4): 398–405

    Article  PubMed  CAS  Google Scholar 

  116. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355(26): 2733–43

    Article  PubMed  CAS  Google Scholar 

  117. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112(3): 533–43

    Article  PubMed  CAS  Google Scholar 

  118. Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15(9): 924–34

    Article  PubMed  CAS  Google Scholar 

  119. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91(4): 639–43

    PubMed  CAS  Google Scholar 

  120. Park YH, Park MJ, Ji SH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009; 100(6): 894–900

    Article  PubMed  CAS  Google Scholar 

  121. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 18(11): 2349–51

    PubMed  CAS  Google Scholar 

  122. Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-cancer Drugs 2007; 18(1): 23–8

    Article  PubMed  CAS  Google Scholar 

  123. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases: the UK experience. Br J Cancer 2010; 102(6): 995–1002

    Article  PubMed  CAS  Google Scholar 

  124. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26(12): 1993–9

    Article  PubMed  CAS  Google Scholar 

  125. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15(4): 1452–9

    Article  PubMed  CAS  Google Scholar 

  126. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27(33): 5538–46

    Article  PubMed  CAS  Google Scholar 

  127. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27(33): 5529–37

    Article  PubMed  CAS  Google Scholar 

  128. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28(7): 1124–30

    Article  PubMed  CAS  Google Scholar 

  129. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28(7): 1138–44

    Article  PubMed  CAS  Google Scholar 

  130. Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010; 10(6): 489–91

    Article  PubMed  Google Scholar 

  131. Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011; 125(2): 447–55

    Article  PubMed  CAS  Google Scholar 

  132. Andre F, Campone M, O’Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28(34): 5110–5

    Article  PubMed  CAS  Google Scholar 

  133. Serra V, Scaltriti M, Prudkin L, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011; 30(22): 2547–57

    Article  PubMed  CAS  Google Scholar 

  134. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25(34): 5410–7

    Article  PubMed  CAS  Google Scholar 

  135. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28(8): 1301–7

    Article  PubMed  CAS  Google Scholar 

  136. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; (3): CD003474

  137. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14(20): 6690–6

    Article  PubMed  CAS  Google Scholar 

  138. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28(35): 5132–9

    Article  PubMed  CAS  Google Scholar 

  139. Van Poznak CH, Temin S, Yee GC, et al. American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29(9): 1221–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Charles Swanton is a Medical Research Council senior clinical research fellow. Sarah Barton would like to thank the Cridlan Fund for supporting her in the funding for preparing this paper. The authors acknowledge National Health Service (UK) funding to the National Institute for Health Research Biomedical Research Centre in assisting with preparation of this paper.

Author information

Authors and Affiliations

  1. Breast Unit, Royal Marsden Hospital, London and Sutton, UK

    Sarah Barton &  Charles Swanton

  2. Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln’s Inn Fields, London, WC2A 3PX, UK

    Charles Swanton

Authors
  1. Sarah Barton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Swanton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles Swanton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barton, S., Swanton, C. Recent Developments in Treatment Stratification for Metastatic Breast Cancer. Drugs 71, 2099–2113 (2011). https://doi.org/10.2165/11594480-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11594480-000000000-00000

Keywords

Search

Navigation